An interventional study of Avoidance and Biospecimen Collection in Cigarette Smoking-Related Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Ohio State University Comprehensive Cancer Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Cigarette Smoking by Ohio State University Comprehensive Cancer Center — 5 open to participants now, 7 under way, none of them phase 3. Cigarette Smoking · Ohio State University Comprehensive Cancer Center.
Among the 14 studies in Cigarette Smoking by Ohio State University Comprehensive Cancer Center, this one is the 12th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, and was the 13th registered.
477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.
Browse Cigarette Smoking studies →5 of the 14 studies in Cigarette Smoking by Ohio State University Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21+ · Healthy volunteers
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21+ · Healthy volunteers
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21+ · Healthy volunteers
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21+ · Healthy volunteers
By country, each count listing its studies:
Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.
This study: 21 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 25 is below the median of 96 across 407 interventional studies indexed under Cigarette Smoking.
Median enrollment 50 across the 13 interventional studies, 182 across the 1 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ohio State University Comprehensive Cancer Center is the lead sponsor of 376 studies on the registry; 82 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 19 (50%) have results posted.
2 of the studies in Cigarette Smoking by Ohio State University Comprehensive Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07111234Ohio State University Comprehensive Cancer CenterStudying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences | 2026-12-31 |
| NCT07455513Ohio State University Comprehensive Cancer CenterA Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Cigarette Smoking by Ohio State University Comprehensive Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates the effect of nicotine on eye movements and related behaviors in people who use electronic (e)-cigarettes. Nicotine is an addictive, poisonous chemical found in tobacco. It can also be made in the laboratory. When it enters the body, nicotine causes an increased heart rate and the use of oxygen by the heart and a sense of well-being and relaxation. E-cigarettes are the most commonly used tobacco products in young adults in the United States. E-cigarettes deliver nicotine rapidly and the potential for addiction (abuse liability) is comparable to combustible cigarettes. The Food and Drug Administration uses a combination of testing including self-reported scales, withdrawal assessments and behavioral tasks to evaluate the abuse liability of a nicotine product. Research has shown that nicotine alters movement of the eye (oculomotor) and the amount of nicotine in the blood impacts the extent of oculomotor function impairment. Despite this evidence linking nicotine to oculomotor changes, it has not been studied as a reliable marker for abuse in e-cigarette users. Studying eye movements can provide information about how the brain responds to nicotine and may help researchers develop better, more objective ways to measure how addictive nicotine products in e-cigarette users.
PRIMARY OBJECTIVE:
I. To determine the between-session reliability of oculomotor biomarkers during standardized nicotine administration in daily e-cigarette users.
SECONDARY OBJECTIVES:
I. To evaluate the association between oculomotor (OM) responses to nicotine and behavioral economic indices of reinforcing value.
II. To assess the relationship between oculomotor changes and nicotine withdrawal relief.
OUTLINE:
Participants abstain from nicotine for at least 12 hours and caffeine products for at least 2 hours, as well as obtain sleep for at least 5-6 hours before each study visit. Participants self-administer 5% nicotine non-mint menthol pods via an e-cigarette device using a guided standardized puffing routine over 5 minutes on visit one. At least 48 hours later, participants complete the same 5-minute guided puffing routine as in visit one and then use an e-cigarette as they normally would over 30 minutes at visit two. Participants also complete eye movement testing and undergo blood sample collection during each visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants abstain from nicotine for at least 12 hours and caffeine products for at least 2 hours, as well as obtain sleep for at least 5-6 hours before each study visit. Participants self-administer 5% nicotine mint menthol via an e-cigarette device using a guided standardized puffing routine over 5 minutes on visit one. At least 48 hours later, participants complete the same 5-minute guided puffing routine as in visit one and then use an e-cigarette as they normally would over 30 minutes at visit two. Participants also complete eye movement testing and undergo blood sample collection during each visit.
Behavioral: Avoidance · Procedure: Biospecimen Collection · Behavioral: Cigarette Smoking · Procedure: Eye Movement Measurement · Behavioral: Healthcare Activity · Other: Questionnaire Administration · Behavioral: Refrain from Smoking · Other: Vaping · Drug: Standardized E-Cigarette Nicotine Administration
Abstain from caffeine products
Also known as: Avoided
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Complete self-administer 5% nicotine non-mint menthol pods via an e-cigarette device
Complete eye movement testing
Obtain sleep
Also known as: Health Care, Health Care Activity, Healthcare
Ancillary studies
Abstain from nicotine
Also known as: Abstain from Smoking, Abstinence from Cigarette Smoking, Abstinence from Cigarettes, Smoking Abstinence
Complete ad-libitum e-cigarette vaping
Also known as: Vape
Participants use a e-cigarette 5.0% nicotine mint menthol pods. Visit 1: 5-minute guided puffing session (standardized protocol). Visit 2: 5-minute guided session followed by 30-minute ad-libitum vaping phase. Puffing topography monitored via SPA-Neo device.
Change in prosaccade latency and velocity
Reliability will be assessed using intraclass correlation coefficients (ICCs). Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures analysis of variance (ANOVA), as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration, assessed up to completion of visit 2, up to 3 weeks
Change in antisaccade error rate and latency
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Change in smooth pursuit gain across two laboratory sessions
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Change in oculomotor performance
Reliability will be assessed using ICCs. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between oculomotor outcomes, plasma nicotine concentrations, subjective ratings, and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: At baseline and at 5, 15 and 30 minutes post-nicotine administration
Plasma nicotine maximum concentration
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
Time to maximum concentration of plasma nicotine
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
Plasma nicotine area under the curve
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between plasma nicotine concentrations and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
Subjective drug liking ratings
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations between subjective ratings and behavioral economic measures will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
Electronic (E)-cigarette intensity demand
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
E-cigarette Omax
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
E-cigarette demand breakpoint
Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Time frame: Up to completion of visit 2, up to 3 weeks
Change in Minnesota Nicotine Withdrawal Scale scores
The Minnesota Nicotine Withdrawal Scale (MNWS) will asses nicotine withdrawal and craving, anger/irritability, anxiety, depressed mood, restlessness/difficulty concentrating, increased appetite, sleep problems, and somatic symptoms (nausea, constipation, sore throat, dizziness, coughing). Scores range from 0 to 4 with higher scores indicating greater levels of withdrawal. Changes will be evaluated using repeated-measures analyses, including mixed-effects models or repeated-measures ANOVA, as appropriate. Associations will be examined using correlation and regression analyses.
Time frame: From baseline and following nicotine administration, assessed up to completion of visit 2, up to 3 weeks
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 16 months is below that.
Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ohio State University Comprehensive Cancer Center →